Zealand Pharma reports positive phase III results against congenital hyperinsulinism

In a phase III study of dasiglucagon, biotech firm Zealand Pharma has met its endpoint, reducing the need for children under 12 months with the rare disorder to undergo intensive hospital treatment by 55%.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

On Thursday, Zealand Pharma has announced positive topline results from a phase III trial of dasiglucagon, a treatment for congenital hyperinsulinism (CHI), the firm reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading